AR047966A1 - Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico - Google Patents
Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropicoInfo
- Publication number
- AR047966A1 AR047966A1 ARP050100612A ARP050100612A AR047966A1 AR 047966 A1 AR047966 A1 AR 047966A1 AR P050100612 A ARP050100612 A AR P050100612A AR P050100612 A ARP050100612 A AR P050100612A AR 047966 A1 AR047966 A1 AR 047966A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 4alkyl
- nr5r6
- group
- 6alkylnr5
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- -1 OC1-6alkyl Chemical group 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229960005222 phenazone Drugs 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101001134805 Homo sapiens Protocadherin alpha-13 Proteins 0.000 abstract 1
- 102100033442 Protocadherin alpha-13 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a compuesto poliheterocíclicos, procesos para s preparacion, composiciones farmacéuticas que contienen dichos compuestos y el uso terapéutico de los mismos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde: P se selecciona entre arilo y heteroarilo; R1 se une a P a través de un átomo de C en el anillo P y se selecciona entre el grupo formado por hidroxi, halo, nitro, C1-6alquilhalo, OC1-6alquilhalo, C1-6 alquilo, OC1-6alquilo, C2- 6alquenilo, OC2-6alquenilo, C2-6 alquinilo, OC2-6 alquinilo, C0-6alquilC3-6cicloalquilo, OC0-6alquilC3-6cicloalquilo, C0-6alquilarilo, OC0-6alquilarilo, CHO, (CO)R5, O(CO)R5, O(CO)OR5, O(CNR5)OR5, C1-6alquilOR5, OC2-6alquilOR5, C1-6alquil(CO)R5, OC1- 6alquil(CO)R5, C0-6alquilCO2R5, OC1-6alquilCO2R5, C0-6alquilciano, OC2-6alquilciano, C0-6alquilNR5R6, OC2-6alquilNR5R6, C1-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, C0-6alquilNR5(CO)R6, OC2-6alquilNR5(CO)R6, C0-6alquil NR5(CO)NR5R6,C0-6alquilSR5, OC2- 6alquilSR5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5, C0-6alquilSO2R5, OC2-6alquilSO2R5, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, C0-6alquilNR5(SO2)NR5R6, OC2-6alquilNR5(SO2)NR5R6, (CO)NR5R6, O(CO)NR5R6, NR5OR6, C0-6alquilNR5(CO)OR6, OC2-6alquilNR5(CO)OR6, SO3R5, y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre el grupo formado por C, N, O y s; X1 se selecciona entre el grupo formado por: N, NR4 y CR4; X2 se selecciona entre el grupo formado por C y N; X3 se selecciona entre el grupo formado por CR4; N y O; X4 se selecciona entre el grupo formado por CR4, N, NR4 y O; X5 se selecciona entre el grupo formado por: un enlace, CR4R4', NR4, O, S, SO, y SO2; X6 se selecciona entre el grupo formado por: CR6 y N; X7 se selecciona entre el grupo formado por: C y N; R4 se selecciona en forma independiente entre un grupo formado por H, hidroxi, C1-6alquilo, C0-6alquilciano, oxo, =NR5, =NOR5, C1- 4alquilhalo, halo, C3-7cicloalquilo, O(CO)C1-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0-4alquilo, OC1-4alquilo, C1-4alquilOR5 y C0-4alquilNR5R6; Q se selecciona del grupo formado por heterocicloalquilo y heteroarilo; R2 y R3 se seleccionan en forma independiente entre el grupo formado por: hidroxi, C0-6alquilciano, oxo, =NR5, =NOR5, C1-4alquilhalo, halo, C1-6alquilo, C3-6cicloalquilo, C0-6alquilarilo, C0-6alquilheteroarilo, C1-6alquilcicloalquilo, C0-6alquilheterocicloalquilo, OC1-4alquilo, OC0-6alquilarilo, O(CO)C1-4alquilo, (CO)OC1-4alquilo, C0-4alquil(S)C0-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0-4alquilo, C1-4alquilOR5, C0-4alquilNR5R6 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre C, N, O y S, y dicho anillo opcionalmente puede fusionarse con un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre el grupo formado por C, N y O y en donde dicho anillo y dicho anillo fusionado pueden sustituirse con uno o más A; en donde cualquier C1-6alquilo, arilo o heteroarilo definido bajo R1, R2 y R3 puede sustituirse con uno o más A; A se selecciona entre el grupo formado por H, hidroxi, halo, nitro, oxo, C0-6alquilciano, C0-4alquilC3-6cicloalquilo, C1-6alquilo, -OC1-6alquilo, C1-6alquilhalo, OC1-6alquilhalo, C2-6alquenilo, C0-3alquilarilo, C0-6alquilOR5, OC2-6alquilOR5, C0-6alquilSR5, OC2-6alquilSR5, (CO)R5, O(CO)R5, OC2-6alquilciano, OC1-6alquilCO2R5, O(CO)OR5, OC1-6alquil(CO)R5, C1-6alquil(CO)R5, NR5OR6, C0-6NR5R6, OC2-6alquilNR5R6, C0-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, OC2-6alquilNR5(CO)R6, C0-6alquilNR5(CO)R6, C0-6alquilNR5(CO)NR5R6, O(CO)NR5R6, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, SO3R5, C1-6alquilNR5(SO2)NR5R6, OC2-6alquil(SO2)R5, C0-6alquil(SO2)R5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre el grupo formado por C, N, O y S; R5 y R6 se seleccionan en forma independiente entre H, C1-6alquilo, C3-7cicloalquilo y arilo; m se selecciona entre 0, 1, 2, 3 o 4; n se selecciona entre 0, 1, 2, 3 o 4; p se selecciona entre 0, 1, 2, 3 o 4; y una sal o hidrato el mismo, con la salvedad de que el compuesto no sea 4,4'-(1,2-piperazinadil)di-antipirina, diclorhidrato de 4,4'-(1,2-piperazinadil)di-antipirina; o dipricato de 4,4'-(1,2- piperazinadil)di-antipirina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54529204P | 2004-02-18 | 2004-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047966A1 true AR047966A1 (es) | 2006-03-15 |
Family
ID=34886130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100612A AR047966A1 (es) | 2004-02-18 | 2005-02-18 | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20070185100A1 (es) |
| EP (1) | EP1716143A1 (es) |
| JP (1) | JP2007523181A (es) |
| KR (1) | KR20070052693A (es) |
| CN (1) | CN1918154A (es) |
| AR (1) | AR047966A1 (es) |
| AU (1) | AU2005214378A1 (es) |
| BR (1) | BRPI0507481A (es) |
| CA (1) | CA2555272A1 (es) |
| IL (1) | IL177058A0 (es) |
| MX (1) | MXPA06009023A (es) |
| NO (1) | NO20063469L (es) |
| NZ (1) | NZ548693A (es) |
| RU (1) | RU2381226C2 (es) |
| SG (1) | SG149900A1 (es) |
| TW (1) | TW200538179A (es) |
| UA (1) | UA82434C2 (es) |
| UY (1) | UY28764A1 (es) |
| WO (1) | WO2005080386A1 (es) |
| ZA (1) | ZA200606314B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2555272A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| SG163577A1 (en) * | 2004-12-03 | 2010-08-30 | Schering Corp | Substituted piperazines as cb1 antagonists |
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| NZ564254A (en) * | 2005-05-18 | 2011-04-29 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| HUP0500921A2 (en) * | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Tetrazole derivatives, process for their preparation and their use |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| TW200808777A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGLUR5 modulators III |
| TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| WO2009005646A2 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| US20100249144A1 (en) * | 2007-06-28 | 2010-09-30 | Demong Duane Eugene | Substituted piperazines as cb1 antagonists |
| CA2703425A1 (en) | 2007-10-19 | 2009-04-23 | Astrazeneca Ab | Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) |
| TW200924774A (en) * | 2007-10-26 | 2009-06-16 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5 |
| WO2009054792A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Aminopyridine derivatives as modulators of mglur5 |
| WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| WO2009054789A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
| WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
| WO2009054793A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mglur5 |
| US8546576B2 (en) * | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US20120040998A1 (en) * | 2009-04-23 | 2012-02-16 | Mercer Swati P | 2-alkyl piperidine mglur5 receptor modulators |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
| CA2912735A1 (en) * | 2013-06-11 | 2014-12-18 | F. Hoffmann-La Roche Ag | Novel tetrazolone derivatives |
| WO2019054427A1 (ja) * | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 環状構造を有する化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83275A (en) * | 1986-09-08 | 1994-02-27 | Novo Nordisk As | Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them |
| EP1210344B1 (en) * | 1999-08-19 | 2005-10-19 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1351951A2 (en) * | 2001-01-05 | 2003-10-15 | Eli Lilly And Company | Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
| JP4303109B2 (ja) * | 2001-10-04 | 2009-07-29 | メルク エンド カムパニー インコーポレーテッド | 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤 |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| SE0201943D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| JP2007510626A (ja) * | 2003-10-17 | 2007-04-26 | アストラゼネカ アクチボラグ | 癌の治療に使用の４−（ピラゾール−３−イルアミノ）ピリミジン誘導体 |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CA2555272A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
-
2005
- 2005-02-17 CA CA002555272A patent/CA2555272A1/en not_active Abandoned
- 2005-02-17 MX MXPA06009023A patent/MXPA06009023A/es active IP Right Grant
- 2005-02-17 BR BRPI0507481-9A patent/BRPI0507481A/pt not_active IP Right Cessation
- 2005-02-17 RU RU2006127572/04A patent/RU2381226C2/ru not_active IP Right Cessation
- 2005-02-17 WO PCT/US2005/005216 patent/WO2005080386A1/en not_active Ceased
- 2005-02-17 NZ NZ548693A patent/NZ548693A/en unknown
- 2005-02-17 CN CNA2005800043398A patent/CN1918154A/zh active Pending
- 2005-02-17 SG SG200900931-7A patent/SG149900A1/en unknown
- 2005-02-17 UA UAA200608216A patent/UA82434C2/uk unknown
- 2005-02-17 EP EP05713792A patent/EP1716143A1/en not_active Withdrawn
- 2005-02-17 KR KR1020067015825A patent/KR20070052693A/ko not_active Ceased
- 2005-02-17 AU AU2005214378A patent/AU2005214378A1/en not_active Abandoned
- 2005-02-17 TW TW094104643A patent/TW200538179A/zh unknown
- 2005-02-17 US US10/588,754 patent/US20070185100A1/en not_active Abandoned
- 2005-02-17 JP JP2006554235A patent/JP2007523181A/ja active Pending
- 2005-02-18 US US11/060,561 patent/US20060025414A1/en not_active Abandoned
- 2005-02-18 AR ARP050100612A patent/AR047966A1/es unknown
- 2005-02-18 UY UY28764A patent/UY28764A1/es unknown
-
2006
- 2006-07-25 IL IL177058A patent/IL177058A0/en unknown
- 2006-07-28 ZA ZA200606314A patent/ZA200606314B/xx unknown
- 2006-07-28 NO NO20063469A patent/NO20063469L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006127572A (ru) | 2008-03-27 |
| KR20070052693A (ko) | 2007-05-22 |
| IL177058A0 (en) | 2006-12-10 |
| CA2555272A1 (en) | 2005-09-01 |
| MXPA06009023A (es) | 2007-03-08 |
| NO20063469L (no) | 2006-11-15 |
| SG149900A1 (en) | 2009-02-27 |
| NZ548693A (en) | 2010-05-28 |
| RU2381226C2 (ru) | 2010-02-10 |
| BRPI0507481A (pt) | 2007-07-17 |
| EP1716143A1 (en) | 2006-11-02 |
| UA82434C2 (uk) | 2008-04-10 |
| ZA200606314B (en) | 2007-12-27 |
| AU2005214378A1 (en) | 2005-09-01 |
| UY28764A1 (es) | 2005-06-30 |
| CN1918154A (zh) | 2007-02-21 |
| JP2007523181A (ja) | 2007-08-16 |
| WO2005080386A1 (en) | 2005-09-01 |
| TW200538179A (en) | 2005-12-01 |
| US20070185100A1 (en) | 2007-08-09 |
| US20060025414A1 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR047812A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
| AR040847A1 (es) | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR041508A1 (es) | Compuestos con actividad en los receptores de glutamato metabotropicos | |
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR065133A1 (es) | Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros. | |
| CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
| AR046992A1 (es) | Derivados de espiro-dihidrobenzofuranos | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |